Evidence about clinical management
The COVID-END inventory is no longer being updated. Below we provide the ‘best’ evidence syntheses currently available as of January 2024 (i.e., the highest quality, most regularly updated living evidence syntheses) about the clinical management of COVID-19. All other evidence syntheses can be found in the searchable COVID-END inventory of evidence syntheses, which is organized using the COVID-END taxonomy of decisions.
In identifying the ‘best’ syntheses, we relied primarily on the three ‘best’ evidence syntheses covering the safety and efficacy of all drug types (rather than syntheses covering single molecules):
- (which maintains a living network meta-analysis about drug treatments, prophylaxis and antibodies and cellular therapies for COVID-19) – you can find the latest peer-reviewed publication in the BMJ for , and , as well as its latest update on this
- (which provided living updates to meta-analyses at the level of individual molecules, however it is no longer being updated, although its last update remains online)
- (which is the second of two groups providing frequent updates to meta-analyses at the level of individual molecules)
| Topic addressed | Criteria for 'best evidence synthesis' | Details to support relevance assessment | Additional decision-relevant details | Citation | ||||
| Date of last search | Quality (AMSTAR) rating | Evidence-certainty (e.g., GRADE) assessment available | Key findings | Living evidence synthesis | Type of synthesis | Type of question | ||
| Drugs to prevent COVID-19 | 2022-03-03 | 10/11 | Yes | See most updated version in this link | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Bartoszko JJ, Siemieniuk RAC, Kum E, Qasim A, Zeraatkar D, Ge L, et al. Prophylaxis for covid-19: Living systematic review and network meta-analysis. The BMJ. 2021;373(8290);n949. |
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||
| Drugs and other treatments for COVID-19 | 2022-03-22 | 10/11 | Yes | Nirmatrelvir (Paxlovid) has not yet been assessed. See most updated version in this link
| Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk R, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021;370:m2980. |
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||
| 2022-12-14 | 10/11 | Yes | A summary of all drugs for hospitalized patients is available here | No | Full review | Benefits and harms | COVID NMA. Pharmacologic treatments for COVID-19 patients. 2021. | |
| Management of post-COVID conditions | 2021-09-25 | 8/11 | No | Yes (row content last checked on 2023-11-05) | Full review | Other | Michelen M, Sigfrid L, Kartsonaki C, Shemilt I, Hastie C, O'Hara ME, Suett JC, Stelson EA, Bugaeva P, Dahmash D, Rigby I. Characterising Long Covid: a living systematic review update with controlled studies. medRxiv. 2022. | |
| 2021-09-02 | 7/11 | No | Yes (row content last checked on 2023-11-05) | Rapid review | Other | de Sire A, Andrenelli E, Negrini, F Iannicelli V Lazzarini SG, Patrini M, Ceravolo MG; International Multiprofessional Steering Committee of Cochrane Rehabilitation REH-COVER action. Rehabilitation and COVID-19: update of the rapid living systematic review by Cochrane Rehabilitation Field as of August 31st, 2021. European Journal of Physical and Rehabilitation Medicine. 2021. | ||
| Managing pandemic-related health impacts | 2022-04-04 | 5/11 | No | Updates published online in this URL () | Yes (row content last checked on 2023-11-05) | Rapid review | Other | Bell V & Wade D. Mental health of clinical staff working in high-risk epidemic and pandemic health emergencies a rapid review of the evidence and living meta-analysis. Social Psychiatry and Psychiatric Epidemiology. 2020. |
| 2021-04-27 | 7/11 | No | Yes (row content last checked on 2023-11-05) | Full review | Other | Sheikh J, Lawson H, Allotey J on behalf of the PregCOV-19 Living Systematic Review Consortium, et alGlobal variations in the burden of SARS-CoV-2 infection and its outcomes in pregnant women by geographical region and country’s income status: a meta-analysis. BMJ Global Health 2022;7:e010060 | ||
Because the searchable COVID-END inventory is organized at the level of an evidence synthesis, we provide below an additional ‘way in’ to the evidence syntheses addressing drugs to prevent or treat COVID-19. Specifically, we summarize what’s known at the level of each individual molecule (e.g., corticosteroids, molnupiravir, tocilizumab), drawing on the first evidence synthesis in the table above.
| Broad and specific decisions | Criteria for 'best evidence synthesis' | Details to support relevance assessment | Additional decision-relevant details | Citation | ||||||
| Date of last search | Quality (AMSTAR) rating | Evidence-certainty (e.g., GRADE) assessment available | Key findings | Living evidence synthesis | Type of synthesis | Type of question | ||||
| Clinical management of COVID-19 and pandemic-related health issues | ||||||||||
| Prophylaxis for COVID-19 | ||||||||||
| Prophylaxis for COVID-19 | ||||||||||
| Drugs to prevent severe COVID-19 infection | 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | |||
| 2022-03-03 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Bartoszko JJ, Siemieniuk RAC, Kum E, Qasim A, Zeraatkar D, Ge L, et al. Prophylaxis for covid-19: Living systematic review and network meta-analysis. The BMJ. 2021;373(8290);n949. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-03-03 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Bartoszko JJ, Siemieniuk RAC, Kum E, Qasim A, Zeraatkar D, Ge L, et al. Prophylaxis for covid-19: Living systematic review and network meta-analysis. The BMJ. 2021;373(8290);n949. | ||||
| 2022-04-27 | 11/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Hirsch C, Valk SJ, Piechotta V, Chai KL, Estcourt LJ, Monsef I, et al. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. Cochrane Database of Systematic Reviews. 2022;(5):CD014945 | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-03-03 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Bartoszko JJ, Siemieniuk RAC, Kum E, Qasim A, Zeraatkar D, Ge L, et al. Prophylaxis for covid-19: Living systematic review and network meta-analysis. The BMJ. 2021;373(8290);n949. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-04-27 | 11/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Hirsch C, Valk SJ, Piechotta V, Chai KL, Estcourt LJ, Monsef I, et al. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. Cochrane Database of Systematic Reviews. 2022;(5):CD014945 | ||||
| 2020-09-21 | 4/9 | No | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM. Update alert 3: Hydroxychloroquine or chloroquine for the treatment or prophylaxis of COVID-19. Annals of Internal Medicine 2020:L20-1257. | ||||
| 2022-03-03 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Bartoszko JJ, Siemieniuk RAC, Kum E, Qasim A, Zeraatkar D, Ge L, et al. Prophylaxis for covid-19: Living systematic review and network meta-analysis. The BMJ. 2021;373(8290);n949. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-04-27 | 11/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Hirsch C, Valk SJ, Piechotta V, Chai KL, Estcourt LJ, Monsef I, et al. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. Cochrane Database of Systematic Reviews. 2022;(5):CD014945 | ||||
| N/A (Protocol) | n/a | Yes | Yes (row content last checked on 2023-11-05) | Protocol | Benefits and harms | Valk SJ, Piechotta V, Kimber C, Chai KL, Doree C, Wood EM, et al. Convalescent plasma and hyperimmune immunoglobulin to prevent infection with SARS鈥怌oV鈥2. Cochrane Database of Systematic Reviews. 2021;CD013802. | ||||
| 2022-03-03 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Bartoszko JJ, Siemieniuk RAC, Kum E, Qasim A, Zeraatkar D, Ge L, et al. Prophylaxis for covid-19: Living systematic review and network meta-analysis. The BMJ. 2021;373(8290);n949. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | Preventative treatments: Hydroxychloroquine vs placebo. COVID NMA; 2020. | ||||
| 2020-09-21 | 4/9 | No | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM. Update alert 3: Hydroxychloroquine or chloroquine for the treatment or prophylaxis of COVID-19. Annals of Internal Medicine 2020:L20-1257. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-03-03 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Bartoszko JJ, Siemieniuk RAC, Kum E, Qasim A, Zeraatkar D, Ge L, et al. Prophylaxis for covid-19: Living systematic review and network meta-analysis. The BMJ. 2021;373(8290);n949. | ||||
| N/A (Protocol) | n/a | Yes | Yes (row content last checked on 2023-11-05) | Protocol | Benefits and harms | Valk SJ, Piechotta V, Kimber C, Chai KL, Doree C, Wood EM, et al. Convalescent plasma and hyperimmune immunoglobulin to prevent infection with SARS鈥怌oV鈥2. Cochrane Database of Systematic Reviews. 2021;CD013802. | ||||
| 2022-03-03 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Bartoszko JJ, Siemieniuk RAC, Kum E, Qasim A, Zeraatkar D, Ge L, et al. Prophylaxis for covid-19: Living systematic review and network meta-analysis. The BMJ. 2021;373(8290);n949. | ||||
| 2022-03-03 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Bartoszko JJ, Siemieniuk RAC, Kum E, Qasim A, Zeraatkar D, Ge L, et al. Prophylaxis for covid-19: Living systematic review and network meta-analysis. The BMJ. 2021;373(8290);n949. | ||||
| 2022-03-03 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Bartoszko JJ, Siemieniuk RAC, Kum E, Qasim A, Zeraatkar D, Ge L, et al. Prophylaxis for covid-19: Living systematic review and network meta-analysis. The BMJ. 2021;373(8290);n949. | ||||
| 2022-04-01 | 11/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Popp M, Stegemann M, Metzendorf MI, Gould S, Kranke P, Meybohm P. Ivermectin for preventing and treating COVID-19. Cochrane Database of Systematic Reviews. 2022;(6):CD015017. | ||||
| 2022-03-03 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Bartoszko JJ, Siemieniuk RAC, Kum E, Qasim A, Zeraatkar D, Ge L, et al. Prophylaxis for covid-19: Living systematic review and network meta-analysis. The BMJ. 2021;373(8290);n949. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-03-03 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Bartoszko JJ, Siemieniuk RAC, Kum E, Qasim A, Zeraatkar D, Ge L, et al. Prophylaxis for covid-19: Living systematic review and network meta-analysis. The BMJ. 2021;373(8290);n949. | ||||
| 2022-03-03 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Bartoszko JJ, Siemieniuk RAC, Kum E, Qasim A, Zeraatkar D, Ge L, et al. Prophylaxis for covid-19: Living systematic review and network meta-analysis. The BMJ. 2021;373(8290);n949. | ||||
| 2022-03-03 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Bartoszko JJ, Siemieniuk RAC, Kum E, Qasim A, Zeraatkar D, Ge L, et al. Prophylaxis for covid-19: Living systematic review and network meta-analysis. The BMJ. 2021;373(8290);n949. | ||||
| 2022-03-03 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Bartoszko JJ, Siemieniuk RAC, Kum E, Qasim A, Zeraatkar D, Ge L, et al. Prophylaxis for covid-19: Living systematic review and network meta-analysis. The BMJ. 2021;373(8290);n949. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| N/A (Protocol) | n/a | No | Yes (row content last checked on 2023-11-05) | Protocol | Benefits and harms | Wang Y, Li B, Zi H, Ma L, Zhao MJ, Huang Q, et al. Effectiveness and safety of chemoprophylaxis for COVID-19: A living systematic review and meta-analysis. PROSPERO. 2020; CRD42020190210 | ||||
| Clinical treatment of COVID-19 | ||||||||||
| Drugs to treat COVID-19 | ||||||||||
| Anti-virals | 2022-12-14 | 10/11 | No | No | Full review | Benefits and harms | Favipiravir vs Baloxavir Marboxil. COVID NMA; 2020. | |||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | No | No | Full review | Benefits and harms | COVID NMA. Darunavir/Cobicistat vs Standard Care. 2020. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Ensitrelvir vs Placebo. 2022 | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Favipiravir vs standard care. 2022. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | Favipiravir vs Umifenovir. COVID NMA; 2020 | ||||
| 2022-03-22 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk R, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021;370:m2980. | ||||
| 2022-12-14 | 10/11 | No | No | Full review | Benefits and harms | Novaferon + Lopinavir + Ritonavir vs Novaferon. COVID NMA; 2020 | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | Lopinavir + Ritonavir vs Standard Care. COVID NMA; 2020 | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Lopinavir-Ritonavir vs Hydroxychloroquine. 2021. | ||||
| 2022-12-14 | 10/11 | No | No | Full review | Benefits and harms | Novaferon vs Lopinavir + Ritonavir. COVID NMA; 2020. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Lopinavir + Ritonavir vs Umifenovir. 2020. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Molnupiravir vs placebo. 2021. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-03-22 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk R, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021;370:m2980. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID-NMA. Nirmatrelvir/ritonavir vs Placebo. 2022 | ||||
| 2022-06-11 | 10/10 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Reis S, Metzendorf M-I, Kuehn R, Popp M, Gagyor I, Kranke P, Meybohm P, Skoetz N, Weibel S. Nirmatrelvir combined with ritonavir for preventing and treating COVID鈥19. Cochrane Database of Systematic Reviews 2022 (9): CD015395 | ||||
| 2022-03-22 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk R, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021;370:m2980. | ||||
| 2023-03-10 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Remdesivir vs standard care/placebo. 2020. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Remdesivir 5 days vs Remdesivir 10 days. 2020. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-05-31 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Grundeis F, Ansems K, Dahms K, Thieme V, Metzendorf M-I, Skoetz N, Benstoem C, Mikolajewska A, Griesel M, Fichtner F, Stegemann M. Remdesivir for the treatment of COVID鈥19. Cochrane Database of Systematic Reviews 2023, 1 (CD014962) | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | Lopinavir + Ritonavir + Ribavirin + Interferon-b-1b vs Lopinavir + Ritonavir. COVID NMA; 2020 | ||||
| 2022-03-22 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk R, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021;370:m2980. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Sofosbuvir/ledipasvir vs Standard care. 2021. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Tenofovir + Emtricitabine vs Standard care. 2022. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | Umifenovir vs Standard Care. COVID NMA; 2020 | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | Favipiravir vs Umifenovir. COVID NMA; 2020 | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Lopinavir + Ritonavir vs Umifenovir. 2020. | ||||
| 2020-07-05 | 5/9 | No | No | Full review | Benefits and harms | Dawoud DM & Soliman KY. Cost-effectiveness of antiviral treatments for pandemics and outbreaks of respiratory illnesses, including COVID-19: A systematic review of published economic evaluations. Value in Health. 2020;23(11):1409-1422. | ||||
| Other antimicrobials | 2022-03-22 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk R, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021;370:m2980. | |||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Hydroxychloroquine + Azithromycin vs Hydroxychloroquine. 2020. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Hydroxychloroquine vs Azithromycin. 2020. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Hydroxychloroquine vs Chloroquine. 2020. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-03-22 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk R, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021;370:m2980. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Ivermectin vs hydroxychloroquine. 2021. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Hydroxychloroquine vs Azithromycin. 2020. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Lopinavir-Ritonavir vs Hydroxychloroquine. 2021. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Hydroxychloroquine+Ribavirin vs Standard care. 2021. | ||||
| 2022-02-28 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Ivermectin vs standard care/placebo. 2020. | ||||
| 2022-03-22 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk R, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021;370:m2980. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2021-05-26 | 11/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Popp M, Stegemann M, Metzendorf MI, Gould S, Kranke P, Meybohm P. Ivermectin for preventing and treating COVID-19. Cochrane Database of Systematic Reviews. 2021;(7):CD015017. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Ivermectin vs hydroxychloroquine. 2021. | ||||
| 2022-02-28 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Colchicine vs Standard Care. 2020. | ||||
| 2022-03-22 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk R, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021;370:m2980. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2021-05-21 | 11/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Mikolajewska A, Fischer AL, Piechotta V, Mueller A, Metzendorf MI, Becker M, et al. Colchicine for the treatment of COVID-19. Cochrane Database of Systematic Reviews. 2021;(10):Art. No.: CD015045. DOI: 10.1002/14651858.CD015045. | ||||
| N/A (Protocol) | n/a | No | Yes (row content last checked on 2023-11-05) | Protocol | Benefits and harms | Urrea G, Meza N, Vargas M, Ortiz L, Rada G, Madrid E. Nonsteroidal Anti-Inflammatory Drugs in Patients with COVID-19: a Living Systematic Review Protocol. PROSPERO 2020; CRD42020179594. | ||||
| Kinase inhibitors | 2020-12-30 | 5/9 | No | No | Full review | Benefits and harms | Stack M, Sacco K, Castagnoli R, Livinski AA, Notarangelo LD, Lionakis MS. BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A systematic review. Research Square. 2021. | |||
| 2022-03-22 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk R, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021;370:m2980. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Baricitinib vs Placebo. 2021. | ||||
| 2020-12-30 | 5/9 | No | No | Full review | Benefits and harms | Stack M, Sacco K, Castagnoli R, Livinski AA, Notarangelo LD, Lionakis MS. BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A systematic review. Research Square. 2021. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. CIGB-325 vs standard care. 2020. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | [Pacritinib] Using pacritinib to treat COVID-19 patients may not have an effect on symptom resolution or clinical improvement, while its effects on other outcomes are currently uncertain | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | |||
| 2022-12-14 | 10/11 | No | No | Full review | Benefits and harms | Ruxolitinib vs Vitamin C. COVID NMA; 2020. | ||||
| 2022-03-22 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk R, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021;370:m2980. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | Tofacitinib vs Placebo. COVID NMA; 2021. | ||||
| 2022-03-22 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk R, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021;370:m2980. | ||||
| Corticosteroids | 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Budesonide vs standard care. 2021. | |||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Ciclesonide vs Standard care/Placebo. 2021. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Corticosteroids vs standard care/placebo. 2021. | ||||
| 2022-03-22 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk R, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021;370:m2980. | ||||
| 2022-03-22 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk R, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021;370:m2980. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-01-06 | 11/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Wagner C, Griesel M, Mikolajewska A, Metzendorf M-I, Fischer A-L, Stegemann M, Spagl M, Nair AAnil, Daniel J, Fichtner F, Skoetz N. Systemic corticosteroids for the treatment of COVID鈥19: Equity鈥恟elated analyses and update on evidence. Cochrane Database of Systematic Reviews 2022 (11): CD014963 | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Dexamethasone High Dose vs Dexamethasone Low Dose. 2022. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| Biologics | 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | |||
| 2020-06-20 | 10/11 | Yes | No | Full review | Benefits and harms | Kim MS, An MH, Kim WJ, Hwang TH. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. PLOS Medicine. 2020;17(12):e1003501. | ||||
| 2021-01-07 | 9/11 | Yes | No | Full review | Benefits and harms | Khan F, Stewart I, Fabbri L, Moss S, Robinson K, Smyth AR, et al. A systematic review of Anakinra, Sarilumab, Siltuximab with meta-analysis of Tocilizumab for Covid-19. Thorax. 2020. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Anakinra vs standard care. 2021. | ||||
| 2021-05-13 | 6/9 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | EUnetHTA Rolling Collaborative Review (RCR09) Authoring Team. APN01 for the treatment of COVID- 19. Diemen (The Netherlands): EUnetHTA; 2020. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Bamlanivimab (LY-CoV555) vs Placebo. 2020. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2021-06-17 | 11/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Kreuzberger N, Hirsch C, Chai KL, Piechotta V, Valk SJ, Estcourt LJ, et al. SARS鈥怌oV鈥2鈥恘eutralising monoclonal antibodies for treatment of COVID鈥19. Cochrane Database of Systematic Reviews. 2021. | ||||
| 2021-07-21 | 11/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, Kum E, Qasim A, Zeraatkar D, et al. Antibody and cellular therapies for treatment of covid-19: A living systematic review and network meta-analysis. BMJ. 2021;374:n2231. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. LY-CoV555+LY-CoV016 vs placebo. 2021. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2021-06-17 | 11/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Kreuzberger N, Hirsch C, Chai KL, Piechotta V, Valk SJ, Estcourt LJ, et al. SARS鈥怌oV鈥2鈥恘eutralising monoclonal antibodies for treatment of COVID鈥19. Cochrane Database of Systematic Reviews. 2021. | ||||
| 2021-07-21 | 11/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, Kum E, Qasim A, Zeraatkar D, et al. Antibody and cellular therapies for treatment of covid-19: A living systematic review and network meta-analysis. BMJ. 2021;374:n2231. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. LY-CoV555+LY-CoV016 vs REGN-COV2. 2021. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Canakinumab vs Placebo. 2021. | ||||
| 2023-11-30 | 10/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 10/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 10/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. LY-CoV555 vs LY-CoV555+LY-CoV016. 2021. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Interferon β vs standard care/placebo. 2020. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | Lopinavir + Ritonavir + Ribavirin + Interferon-b-1b vs Lopinavir + Ritonavir. COVID NMA; 2020 | ||||
| 2022-03-22 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk R, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021;370:m2980. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Interferon α-2b + Interferon gamma+ vs Interferon α-2b. 2020. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Itolizumab vs standard care. 2020. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-03-22 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk R, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021;370:m2980. | ||||
| 2020-07-01 | 7/11 | No | No | Full review | Benefits and harms | Talaie H, Hosseini SM, Nazari M, et al. Is there any potential management against COVID-19? A systematic review and meta-analysis [published online ahead of print, 2020 Aug 18]. Daru. 2020;1-13. doi:10.1007/s40199-020-00367-4 | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | No | No | Full review | Benefits and harms | Novaferon + Lopinavir + Ritonavir vs Lopinavir + Ritonavir. COVID NMA; 2020 | ||||
| 2022-12-14 | 10/11 | No | No | Full review | Benefits and harms | Novaferon vs Lopinavir + Ritonavir. COVID NMA; 2020. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Otilimab vs placebo. 2022. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Peginterferon Lambda-1 vs placebo. 2020. | ||||
| 2023-11-30 | 10/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. rSIFN-co vs IFN-alpha. 2020. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2021-06-17 | 11/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Kreuzberger N, Hirsch C, Chai KL, Piechotta V, Valk SJ, Estcourt LJ, et al. SARS鈥怌oV鈥2鈥恘eutralising monoclonal antibodies for treatment of COVID鈥19. Cochrane Database of Systematic Reviews. 2021. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Regdanvimab vs placebo. 2022 | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2021-06-17 | 11/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Kreuzberger N, Hirsch C, Chai KL, Piechotta V, Valk SJ, Estcourt LJ, et al. SARS鈥怌oV鈥2鈥恘eutralising monoclonal antibodies for treatment of COVID鈥19. Cochrane Database of Systematic Reviews. 2021. | ||||
| 2021-07-21 | 11/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, Kum E, Qasim A, Zeraatkar D, et al. Antibody and cellular therapies for treatment of covid-19: A living systematic review and network meta-analysis. BMJ. 2021;374:n2231. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. REGN-COV2 vs placebo. 2020. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Sarilumab vs standard care. 2020. | ||||
| 2021-01-07 | 9/11 | Yes | No | Full review | Benefits and harms | Khan F, Stewart I, Fabbri L, Moss S, Robinson K, Smyth AR, et al. A systematic review of Anakinra, Sarilumab, Siltuximab with meta-analysis of Tocilizumab for Covid-19. Thorax. 2020. | ||||
| 2022-03-22 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk R, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021;370:m2980. | ||||
| 2021-02-26 | 9/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Ghosn L, Chaimani A, Evrenoglou T, Davidson M, Graña C, Schmucker C, et al. Interleukin鈥6 blocking agents for treating COVID鈥19: A living systematic review. Cochrane Database of Systematic Reviews. 2021. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2021-01-07 | 9/11 | Yes | No | Full review | Benefits and harms | Khan F, Stewart I, Fabbri L, Moss S, Robinson K, Smyth AR, et al. A systematic review of Anakinra, Sarilumab, Siltuximab with meta-analysis of Tocilizumab for Covid-19. Thorax. 2020. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-03-22 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk R, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021;370:m2980. | ||||
| 2022-03-22 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk R, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021;370:m2980. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Tocilizumab vs standard care/placebo. 2021. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Tocilizumab vs Dexamethasone. 2021. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2021-06-17 | 11/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Kreuzberger N, Hirsch C, Chai KL, Piechotta V, Valk SJ, Estcourt LJ, et al. SARS鈥怌oV鈥2鈥恘eutralising monoclonal antibodies for treatment of COVID鈥19. Cochrane Database of Systematic Reviews. 2021. | ||||
| 2021-07-21 | 11/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, Kum E, Qasim A, Zeraatkar D, et al. Antibody and cellular therapies for treatment of covid-19: A living systematic review and network meta-analysis. BMJ. 2021;374:n2231. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Sotrovimab vs Placebo. 2021. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Sotrovimab vs Casirivimab+Imdevimab (REGN-COV2). 2021. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2021-02-04 | 9/11 | No | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Tleyjeh IM, Kashour Z, Riaz M, Hassett L, Veiga VC, Kashour T. Efficacy and safety of tocilizumab in COVID-19 patients: A living systematic review and meta-analysis: First update. Clinical Microbiology and Infection. 2021. Epub ahead of print. | ||||
| 2021-02-26 | 9/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Ghosn L, Chaimani A, Evrenoglou T, Davidson M, Graña C, Schmucker C, et al. Interleukin鈥6 blocking agents for treating COVID鈥19: A living systematic review. Cochrane Database of Systematic Reviews. 2021. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Vilobelimab vs placebo/standard care. 2022. | ||||
| Others | 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | a-Lipoic Acid vs Placebo. COVID NMA; 2020 | |||
| 2020-07-31 | 6/6 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Meza N, Pérez-Bracchiglione J, Pérez I, Carvajal C, Ortiz-Muñoz L, Olguín P, et al. Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers for COVID-19: A living systematic review of randomized clinical trials. Medwave. 2021;21(2):e8105. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Auxora vs standard care. 2020. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Camostat Mesilate vs Placebo. 2021. | ||||
| 2020-04-23 | 5/6 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Rada G, Corbalan J, Rojas P. Cell-based therapies for COVID-19: A living systematic review. Medwave. 2020;20(11):e8079. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Recombinant human granulocyte colony-stimulating factor vs standard care. 2020. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. C1 Esterase/Kallikrein inhibitor vs standard care. 2020. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2020-09-20 | 8/11 | Yes | No | Full review | Benefits and harms | Sethia R, Prasad M, Jagannath S, Nischal N, Soneja M, Garg P, et al. Efficacy of Famotidine for COVID-19: A Systematic Review and Meta-analysis. medRxiv. 2020. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Fluvoxamine vs placebo. 2020. | ||||
| 2022-02-01 | 10/10 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Nyirenda JLZ, Sofroniou M, Toews I, Mikolajewska A, Lehane C, Monsef I, Abu-taha A, Maun A, Stegemann M, Schmucker C. Fluvoxamine for the treatment of COVID鈥19. Cochrane Database of Systematic Reviews 2022 (9): CD015391 | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Losartan vs Standard care/Placebo. 2021 | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Nafamostat vs Standard care. 2021. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Sargramostim vs Standard care. 2022. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2021-05-11 | 6/9 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | EUnetHTA Rolling Collaborative Review (RCR06) Authoring Team. Solnatide for the treatment of COVID-19. Diemen (The Netherlands): EUnetHTA; 2021 | ||||
| 2020-07-27 | 7/10 | No | No | Full review | Benefits and harms | Kow CS & Hasan SS. Meta-analysis of effect of statins in patients with COVID-19. The American Journal of Cardiology. 2020. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Human umbilical cord mesenchymal stem cell infusion vs standard care/placebo. 2020. | ||||
| 2022-03-22 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk R, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021;370:m2980. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Vitamin D vs standard care/placebo. 2020. | ||||
| 2022-03-22 | 10/11 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Siemieniuk R, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021;370:m2980. | ||||
| 2021-03-11 | 9/10 | Yes | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Stroehlein JK, Wallqvist J, Iannizzi C, Mikolajewska A, Metzendorf MI, Benstoem C, et al. Vitamin D supplementation for the treatment of COVID-19: A living systematic review. Cochrane Database of Systematic Rev.iews 2021;5:CD015043. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Hydroxychloroquine+Zinc vs Hydroxychloroquine. 2020. | ||||
| Other treatments for COVID-19 | 2022-03-30 | 8/11 | No | Yes (row content last checked on 2023-11-05) | Full review | Benefits and harms | Kirkham, A. M., Bailey, A. J., Shorr, R., Lalu, M. M., Fergusson, D. A., & Allan, D. S. (2022). Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat COVID-19: Is it too late?. Cytotherapy. | |||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2021-04-20 | 5/10 | No | No | Full review | Benefits and harms | Prakash A, Kaur S, Kaur C, Prabha PK, Bhatacharya A, Sarma P, et al. Efficacy and safety of inhaled nitric oxide in the treatment of severe/critical COVID-19 patients: A systematic review. Indian Journal of Pharmacology. 2021;53(3):236-243. | ||||
| 2022-12-14 | 10/11 | Yes | No | Full review | Benefits and harms | COVID NMA. Photobiomodulation therapy vs Standard care/Placebo. 2021. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| 2023-11-30 | 7/11 | Yes | Yes (row content last checked on 2023-12-31) | Rapid review | Benefits and harms | Pan American Health Organization. Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence. Rapid Review, 30 November 2023. Washington, DC: Pan American Health Organization. 2023. | ||||
| N/A (Protocol) | n/a | Yes | Yes (row content last checked on 2023-11-05) | Protocol | Other | Pardo SA, Lai S, Ortiz-Munoz L, Bravo-Jeria R, Verdugo-Paiva F, Rada G, et al. Pulmonary rehabilitation for COVID-19: A living systematic review protocol. Medwave. 2021;21(6):e8224. | ||||
This work is licensed under a .